[1] |
JIA L F, DU Y F, CHU L, et al. Prevalence,risk factors,and management of dementia and mild cognitive impairment in adults aged 60 years or older in China:a cross-sectional study[J]. Lancet Public Health, 2020, 5(12):e661-671. DOI: 10.1016/S2468-2667(20)30185-7.
|
[2] |
|
[3] |
REN R J, QI J L, LIN S H, et al. The China alzheimer report 2022[J]. Gen Psychiatr, 2022, 35(1):e100751. DOI: 10.1136/gpsych-2022-100751.
|
[4] |
NORTON S, MATTHEWS F E, BARNES D E, et al. Potential for primary prevention of Alzheimer's disease:an analysis of population-based data[J]. Lancet Neurol, 2014, 13(8):788-794. DOI: 10.1016/S1474-4422(14)70136-X.
|
[5] |
|
[6] |
KUZUYA M. Era of geriatric medical challenges:multimorbidity among older patients[J]. Geriatr Gerontol Int, 2019, 19(8):699-704. DOI: 10.1111/ggi.13742.
|
[7] |
YAO S S, CAO G Y, HAN L, et al. Prevalence and patterns of multimorbidity in a nationally representative sample of older Chinese:results from the China health and retirement longitudinal study[J]. J Gerontol A Biol Sci Med Sci, 2020, 75(10):1974-1980. DOI: 10.1093/gerona/glz185.
|
[8] |
ARAMRAT C, CHOKSOMNGAM Y, JIRAPORNCHAROEN W, et al. Advancing multimorbidity management in primary care:a narrative review[J]. Prim Health Care Res Dev, 2022, 23:e36. DOI: 10.1017/s1463423622000238.
|
[9] |
|
[10] |
|
[11] |
刘云. 岳阳市岳阳楼区65岁以上老年期痴呆患病率及危险因素的调查[D]. 衡阳:南华大学,2017.
|
[12] |
GALVIN J E, ROE C M, POWLISHTA K K, et al. The AD8:a brief informant interview to detect dementia[J]. Neurology, 2005, 65(4):559-564. DOI: 10.1212/01.wnl.0000172958.95282.2a.
|
[13] |
CHAN T S F, LAM L C W, CHIU H F K, et al. Validity and applicability of the Chinese version of community screening instrument for dementia[J]. Dement Geriatr Cogn Disord, 2002, 15(1):10-18. DOI: 10.1159/000066672.
|
[14] |
ZHANG Z X, ZAHNER G E P, ROMÁN G C, et al. Dementia subtypes in China[J]. Arch Neurol, 2005, 62(3):447. DOI: 10.1001/archneur.62.3.447.
|
[15] |
NASREDDINE Z S, PHILLIPS N A, BEDIRIAN V, et al. The Montreal cognitive assessment,MoCA:a brief screening tool for mild cognitive impairment[J]. J Am Geriatr Soc, 2005, 53(4):695-699. DOI: 10.1111/j.1532-5415.2005.53221.x.
|
[16] |
史荔月. 遵义市城乡老年人群痴呆患病率与危险因素的特征分析[D]. 遵义:遵义医科大学,2022.
|
[17] |
|
[18] |
RAMOS-CEJUDO J, WISNIEWSKI T, MARMAR C, et al. Traumatic brain injury and Alzheimer's disease:the cerebrovascular link[J]. EBioMedicine, 2018, 28:21-30. DOI: 10.1016/j.ebiom.2018.01.021.
|
[19] |
LI Y H, LAWS S M, MILES L A, et al. Genomics of Alzheimer's disease implicates the innate and adaptive immune systems[J]. Cell Mol Life Sci, 2021, 78(23):7397-7426. DOI: 10.1007/s00018-021-03986-5.
|
[20] |
LENNON M J, KONCZ R, SACHDEV P S. Hypertension and Alzheimer's disease:is the picture any clearer?[J]. Curr Opin Psychiatry,2021,34(2):142-148.
|
[21] |
FREITAS G B, LOURENCO M V, DE FELICE F G. Protective actions of exercise-related FNDC5/Irisin in memory and Alzheimer's disease[J]. J Neurochem, 2020, 155(6):602-611. DOI: 10.1111/jnc.15039.
|
[22] |
XU Y T, YAN H, ZHANG X, et al. Roles of altered macrophages and cytokines:implications for pathological mechanisms of postmenopausal osteoporosis,rheumatoid arthritis,and alzheimer's disease[J]. Front Endocrinol (Lausanne), 2022, 13:876269. DOI: 10.3389/fendo.2022.876269.
|
[23] |
FORMAN H J, ZHANG H Q. Author Correction:targeting oxidative stress in disease:promise and limitations of antioxidant therapy[J]. Nat Rev Drug Discov, 2021, 20(8):652. DOI: 10.1038/s41573-021-00233-1.
|
[24] |
Inflammatory bowel disease:a potential pathogenic factor of Alzheimer's disease[J]. Prog Neuro Psychopharmacol Biol Psychiatry, 2022, 119:110610. DOI: 10.1016/j.pnpbp.2022.110610.
|
[25] |
HEAD A, FLEMING K, KYPRIDEMOS C, et al. Multimorbidity:the case for prevention[J]. J Epidemiol Community Health, 2021, 75(3):242-244. DOI: 10.1136/jech-2020-214301.
|
[26] |
|